Expertise in
7
conditions

Dr. David J. Prelutsky

Internal Medicine
Walgreens Specialty Pharmacy #12927
2340 Hampton Ave, 
Saint Louis, MO 
Accepting New Patients
Expertise in
7
conditions
Walgreens Specialty Pharmacy #12927
2340 Hampton Ave, 
Saint Louis, MO 

Overview

David Prelutsky is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri.

Dr. Prelutsky is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Myelitis, HIV/AIDS, AIDS Dementia Complex, and AIDS Dysmorphic Syndrome.

He is actively involved in clinical research, participating in 4 clinical trials. Dr. Prelutsky is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in MO

Hospital Affiliations

Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Missouri Baptist Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Celtic
  • HMO
  • INSURANCE PLAN
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Sutter Health
  • HMO
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 23 Less Insurance Carriers -

Locations

Walgreens Specialty Pharmacy #12927
2340 Hampton Ave, Saint Louis, MO 63139

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: July 19, 2023
Intervention Type: Drug
Study Drugs: Dolutegravir+Lamivudine, Tenofovir alafenamide based regimen
Study Phase: Phase 3
Open-label Switch Study From a Regimen of Elvitegravir/Tenofovir Alafenamide/Emtricitabine/Cobicistat and Darunavir, to a FDC of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed HIV-l Subjects Known to Have an 184 V/I Mutation
Open-label Switch Study From a Regimen of Elvitegravir/Tenofovir Alafenamide/Emtricitabine/Cobicistat and Darunavir, to a FDC of Bictegravir/Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed HIV-l Subjects Known to Have an 184 V/I Mutation
Enrollment Status: Terminated
Publish Date: January 05, 2023
Intervention Type: Drug
Study Drug: Biktarvy Tab
Study Phase: Phase 4
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
View 3 Less Clinical Trials
Similar Doctors
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine
Expertise in
28
conditions
Dr. Michael P. Whyte
Internal Medicine

Office

4921 Parkview Pl Ste 5C, 
Saint Louis, MO 
 (1.9 miles away)
314-454-7775
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Michael Whyte is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Whyte is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Hypophosphatasia (HPP), Juvenile Paget's Disease, Rickets, Osteopetrosis, and Leg or Foot Amputation. Dr. Whyte is currently accepting new patients.

Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine
Expertise in
13
conditions
Dr. John C. Morris
Internal Medicine

Office

4488 Forest Park Ave Ste 160, 
Saint Louis, MO 
 (2.8 miles away)
314-286-1967
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Morris is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Morris is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Alzheimer's Disease, Dementia, Primary Amyloidosis, Thyroidectomy, and Vertebroplasty. Dr. Morris is currently accepting new patients.

Expertise in
11
conditions
Dr. Daniel C. Link
Internal Medicine
Expertise in
11
conditions
Dr. Daniel C. Link
Internal Medicine

Barnes-Jewish Hospital

1 Barnes Jewish Hospital Plz, 
Saint Louis, MO 
 (1.9 miles away)
314-454-8304
Languages Spoken:
English

Daniel Link is a primary care provider, practicing in Internal Medicine in Saint Louis, Missouri. Dr. Link is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Agranulocytosis, Severe Congenital Neutropenia, Cyclic Neutropenia, and Chronic Familial Neutropenia.

Frequently Asked Questions about Dr. David J. Prelutsky

How do I make an appointment with Dr. David J. Prelutsky?

You can book an appointment with Dr. David J. Prelutsky by calling their office at 314-647-2200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David J. Prelutsky a top-rated expert for Myelitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David J. Prelutsky is classified as an Advanced expert for Myelitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David J. Prelutsky specialize in?

While Dr. David J. Prelutsky is a Internal Medicine, they have specific expertise in Myelitis, HIV/AIDS, and AIDS Dementia Complex. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. David J. Prelutsky accept my insurance?

Dr. David J. Prelutsky accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 314-647-2200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prelutsky's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 53 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile